Table 1 Preliminary antifungal activities in vitro of compounds 4a–4k at 100 µg/mLa.
No. | Average inhibition rate ± SD (%) (n = 3) (100 µg/mL, 72 h) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
FG | AS | AB | AA | CL | CG | FB | VM | PO | PP | |
Andro | 20.5 ± 0.4 | 34.8 ± 1.0 | 25.8 ± 0.9 | 20.8 ± 0.6 | 33.5 ± 1.2 | 38.2 ± 0.4 | 36.8 ± 1.2 | 18.4 ± 0.0 | 28.9 ± 0.8 | 42.1 ± 0.2 |
4a | 29.8 ± 1.7 | 44.2 ± 0.0 | 12.9 ± 2.0 | 27.8 ± 0.0 | 60.3 ± 1.6 | 29.0 ± 1.8 | 30.7 ± 1.5 | 21.9 ± 1.0 | 22.9 ± 1.0 | 25.9 ± 2.1 |
4b | 43.6 ± 0.7 | 50.6 ± 1.7 | 53.8 ± 2.3 | 61.4 ± 1.9 | 38.4 ± 0.8 | 69.4 ± 1.1 | 41.4 ± 1.4 | 55.7 ± 2.3 | 27.0 ± 2.1 | 32.4 ± 0.0 |
4c | 34.7 ± 0.7 | 48.0 ± 1.0 | 50.3 ± 2.0 | 50.8 ± 0.9 | 56.4 ± 0.8 | 67.7 ± 0.0 | 58.6 ± 0.8 | 38.7 ± 1.5 | 55.2 ± 1.1 | 35.8 ± 0.0 |
4d | 71.2 ± 1.9 | 75.0 ± 1.0 | 62.4 ± 0.0 | 46.5 ± 0.0 | 56.9 ± 0.8 | 64.4 ± 1.9 | 65.6 ± 0.0 | 46.7 ± 0.9 | 55.4 ± 1.1 | 83.6 ± 0.0 |
4e | 42.1 ± 0.7 | 46.2 ± 0.0 | 41.1 ± 1.1 | 45.4 ± 0.9 | 51.6 ± 1.5 | 53.8 ± 1.1 | 48.4 ± 0.0 | 38.2 ± 1.7 | 46.0 ± 1.1 | 40.9 ± 2.0 |
4f | 34.3 ± 0.0 | 68.6 ± 2.0 | 40.4 ± 2.0 | 48.7 ± 0.9 | 70.2 ± 1.5 | 57.6 ± 2.2 | 38.1 ± 0.8 | 42.7 ± 1.5 | 41.7 ± 2.1 | 48.0 ± 1.7 |
4g | 43.4 ± 1.4 | 45.1 ± 2.0 | 50.3 ± 2.0 | 44.3 ± 1.9 | 80.9 ± 0.8 | 70.9 ± 1.1 | 73.5 ± 0.8 | 53.8 ± 0.9 | 47.2 ± 1.1 | 49.1 ± 21.5 |
4h | 26.9 ± 0.0 | 40.5 ± 2.0 | 9.3 ± 1.1 | 13.5 ± 0.9 | 52.4 ± 1.5 | 31.0 ± 4.4 | 19.1 ± 1.4 | 18.6 ± 1.5 | 20.9 ± 0.0 | 19.1 ± 1.0 |
4i | 26.0 ± 0.7 | 37.0 ± 2.0 | 7.3 ± 1.1 | 12.4 ± 2.8 | 52.4 ± 1.5 | 32.3 ± 2.2 | 24.2 ± 0.8 | 26.6 ± 0.9 | 22.1 ± 2.1 | 12.9 ± 1.0 |
4j | 31.0 ± 0.7 | 41.0 ± 3.0 | 11.3 ± 1.1 | 2.2 ± 0.9 | 12.4 ± 0.8 | 17.1 ± 2.2 | 14.0 ± 0.8 | 16.1 ± 1.7 | 6.7 ± 1.1 | 15.3 ± 0.0 |
4k | 42.6 ± 1.4 | 86.5 ± 1.0 | 33.9 ± 3.0 | 22.7 ± 1.9 | 62.2 ± 1.5 | 44.6 ± 0.0 | 28.8 ± 0.0 | 38.7 ± 0.9 | 43.1 ± 1.1 | 40.0 ± 2.0 |
KXMb | 60.9 ± 1.9 | 55.4 ± 2.5 | 60.9 ± 1.9 | 55.4 ± 2.5 | 60.9 ± 1.9 | 55.4 ± 2.5 | 60.9 ± 1.9 | 55.4 ± 2.5 | 60.9 ± 1.9 | 55.4 ± 2.5 |
